Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GlycanAge is a longevity-focused biotechnology company that provides a biological age testing service based on glycan analysis. The company utilizes proprietary technology to measure Immunoglobulin G (IgG) glycosylation, which serves as a biomarker for chronic inflammation and biological aging. By analyzing the complex sugar molecules attached to antibodies, GlycanAge offers insights into an individual's health span and the effectiveness of lifestyle interventions. The company's science is rooted in decades of research conducted at the Genos Glycoscience Research Institution, involving large-scale clinical cohorts. GlycanAge targets both the direct-to-consumer market and healthcare professionals looking to integrate personalized longevity metrics into their practice. Their mission is to empower individuals to manage their health proactively by tracking the molecular drivers of aging.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GlycanAge.